clinical aspect of general anesthetics james q. swift d.d.s. oral and maxillofacial surgery pharm...

58
Clinical Aspect of Clinical Aspect of General Anesthetics General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Post on 21-Dec-2015

218 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Clinical Aspect of Clinical Aspect of General AnestheticsGeneral Anesthetics

James Q. Swift D.D.S.Oral and Maxillofacial

Surgery

Pharm PHCL 5-103

Page 2: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

AnxietyAnxiety

Probably the most frequent etiologic factor in the generation of a medical emergency

In combination with a labile medically compromised patient, contributes to medical crisis and possible fatality

Can be effectively managed in many ways, including the use of sedation and anesthesia

Page 3: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 4: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Anxiety and Pain ControlAnxiety and Pain Control

General Anesthesia=unconsciousness

Sedation=diminished consciousness

Nitrous oxide=sedation

Page 5: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 6: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 7: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Behavioral Behavioral Manifestations of Manifestations of

Anesthesia (Guedel)Anesthesia (Guedel) Stage I - Analgesia Stage II - Delirium Stage III - Surgical Anesthesia

– Plane 1– Plane 2– Plane 3– Plane 4

Stage IV - Medullary Paralysis

Page 8: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

FIGURE 18-2FIGURE 18-2 Guedel’s scheme of progressive CNS depression Guedel’s scheme of progressive CNS depression produced by the anesthetic ether. Changes in physiologic produced by the anesthetic ether. Changes in physiologic functions are shown for the different stages and planes functions are shown for the different stages and planes of Guedel’s classification. Examples of surgery that can of Guedel’s classification. Examples of surgery that can by performed at there anesthetic levels are given in by performed at there anesthetic levels are given in parentheses. parentheses.

Page 9: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Anxiety and Pain ControlAnxiety and Pain Control

General Anesthesia– Intravenous– Inhalational

Parenteral Sedation (Conscious Sedation)– Intravenous– Intramuscular– Submucosal

Enteral Sedation (Oral Sedation) Nitrous Oxide Sedation

Page 10: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Conscious SedationConscious Sedation

CNS depression: not unconscious– amnesia

– diminished ability to respond to command

– diminished ability to remain unobstructed

Page 11: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Big RisksBig Risks Obesity Asthma/Pulmonary disease Hypomobility of the mandible: “locked jaw” Extremes of age

Page 12: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Respiratory DifficultyRespiratory Difficulty Airway obstruction Respiratory arrest Cardiac failure/acute pulmonary edema Laryngospasm Bronchospasm

– asthma– allergic reaction

Page 13: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Mortality StatisticsMortality Statistics

Death/serious disability in the office practice of OMS is 1:>800,000 anesthetics

Page 14: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Anesthetic Agents Commonly Anesthetic Agents Commonly Used with a GA in the OMS Used with a GA in the OMS

EnvironmentEnvironment Benzodiazepine

– Midazolam– Diazepam

Opioid– Meperidine– Fentanyl

Barbiturate– Sodium methohexital

Propofol Ketamine Inhalational agent

– Isoflurane, Sevoflurane, Halothane

Page 15: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Point to RememberPoint to Remember

Any anesthetic/sedative/opioid regardless of route of administration can be a general anesthetic (can cause unconsciousness)

Page 16: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Routes for Delivery of Routes for Delivery of General AnestheticsGeneral Anesthetics

Intravenous (IV) Inhalational

Page 17: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Types of General Types of General AnestheticsAnesthetics

Induction agents– Induction agents usually administered IV

– can be inhalational for those who do not tolerate IV access

Maintenance agents– Maintenance agents usually administered inhalationally or IV with bolus or continuous infusion technique

Page 18: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

FIGURE 19-1FIGURE 19-1 Structural formulas of anesthetic drugs. Structural formulas of anesthetic drugs.

Page 19: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Intravenous AgentsIntravenous Agents

Primary role as induction agents Maintenance with total intravenous anesthesia– Rapid redistribution– Shorter half lives– Environmental risk of inhalational agents

Rapid distribution to vessel rich tissues

Page 20: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-IntravenousIntravenous

AgentsAgents High lipid solubility allows for rapid induction

When redistributed out of the brain, effect decreases

Advantages– Rapid and complete induction– Less CV depression

Page 21: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 22: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Intravenous AgentsIntravenous Agents

Benzodiazepines– Rarely used alone for general anesthesia

Cannot easily induce and maintain general anesthesia

Lack analgesic properties

– Used for sedative and amnestic effects Opioids

– Decrease MAC of inhalation agents– Primarily used as adjuncts– Respiratory depression

Page 23: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Intravenous AgentsIntravenous Agents

Ketamine– Duration of anesthesia 5-20 minutes– Metabolized in the liver– Increase in HR, BP, and CO due to sympathomimetic effects

– Do not use in patients that will not tolerate above

– Stimulates salivary secretions– Emergence phenomenon 5-30%

Page 24: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Intravenous AgentsIntravenous Agents

Ketamine– “Dissociative anesthesia”

Amnesia Analgesia Catalepsy

– Thalamoneocortical and limbic systems– Protective reflexes maintained– NMDA antagonist

Page 25: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Intravenous AgentsIntravenous Agents

Ketamine (cont.)– Affects mu opioid receptors– Onset and peak plasma concentrations

1 minute after IV 5-15 minutes after IM 30 minutes after oral

– Distributional half life 11-16 minutes– Elimination half life 2-3 hours

Page 26: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Intravenous AgentsIntravenous Agents

Methohexital– 2.5 times more potent than thiopental– Shorter duration of action– Sleep time 5-7 minutes– Mean elimination half life 3.9 hours– Biotransformed in the liver– Excitatory phenomena– Most often used GA in OMS

Page 27: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Intravenous AgentsIntravenous Agents

Propofol– Unrelated to other general anesthetics– Oil in water emulsion– Rapid onset– Distributional half life 1-8 minutes– Terminal elimination half life 4-24 hours

– Extensive plasma and tissue protein binding

Page 28: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Intravenous AgentsIntravenous Agents

Propofol (cont.)– Disappears from bloodstream more rapidly than thiopental

– Decreases MAP 20-30 %– Apnea 22-45% after induction dose– Pain on injection– Less N & V– Discard unused portion after 6 hours

Page 29: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Inhalational General Inhalational General AnestheticsAnesthetics

Page 30: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Inhalational Anesthetics Inhalational Anesthetics Uptake and DistributionUptake and Distribution

Blood solubility- low, intermediate and high

Muscle has an affinity for anesthetic agents similar to that of blood

Lipids have a high affinity for anesthetic agents

Page 31: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

MAC-MAC-MMinimum inimum AAlveolar lveolar CConcentrationoncentration

The amount of anesthetic gas that will provide surgical anesthesia so that 50% of the subjects will not respond to the surgical incision

Page 32: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 33: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Elimination and Elimination and Metabolism of Anesthetic Metabolism of Anesthetic

GasesGases Same factors apply as uptake regarding gas principles

Most agents are biotransformed in the liver to some degree

Page 34: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Pharmacologic Effects of Pharmacologic Effects of Inhalation AgentsInhalation Agents

CV– Depression of myocardial contractility

Sensitivity to catecholamines Concerns regarding bradycardia

– Decrease of peripheral vascular resistance Effect is hypotension

Respiration– Depression of medullary responses and respiration

Page 35: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 36: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Inhalational AgentsInhalational Agents

Nitrous Oxide– MAC is 105%– Blood/gas partition coefficient 0.47– With other Gas, concentration is 50-70%– Little effect on respiration– Eliminated unchanged– Dysphoria and nausea with increased concentrations– Diffusion hypoxia– Can induce changed in folate and amino acid metabolism

Page 37: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetics-General Anesthetics-Inhalational AgentsInhalational Agents

Sevoflurane– MAC 2.05%– Mild airway irritant– Suitable for mask induction– Rare hepatotoxicity

Page 38: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Inhalational AgentsInhalational Agents Desflurane

– Blood gas partition coefficient 0.42– Irritating to airway– MAC 6%– Required heated vaporizer– Expensive compared to other anesthetic gases– Reduces SVR and MAP, but increase in heart rate causing stable CO

– Low risk of hepatotoxicity– Rapid depth and recovery

Page 39: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Inhalational AgentsInhalational Agents

Isoflurane (Forane)– Anesthesia of choice– Blood/gas partition coefficient 1.4 MAC 1.15%

– “Pungent” odor– Can provide muscle relaxation (high concentrations)

– Dose dependent depression of myocardial contractility

– Coronary vasodilation– CO maintained– Can use catecholamines

– Respiratory depression

– Neither nephrotoxic or hepatotoxic

Page 40: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Inhalational AgentsInhalational Agents

Halothane– Halogenated hydrocarbon– MAC is 0.75%– Blood/gas partition coefficient 2.3– Poor analgesic properties– Incomplete muscle relaxation– Decreased MAP– Depressant effect on myocardial contractility

Page 41: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Inhalational AgentsInhalational Agents

Halothane (cont.)– Vasodilator– Depressant effect on respiration– Elimination-alveolar excretion and hepatic metabolism

– Sensitizes heart to catecholamines– Associated with hepatoxicity– Malignant hyperthermia

Page 42: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 43: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 44: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthesia in a General Anesthesia in a Hospital Operating Room or Hospital Operating Room or Outpatient Surgical CenterOutpatient Surgical Center

NPO Intravenous access Preanesthetic sedative

Induction agent (general anesthetic)

Muscle relaxant Intubation

Maintenance of the anesthetic (general anesthetic)

Emergence Recovery Average time > 30 minutes-several hours

Patient supine (prone)

Page 45: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 46: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 47: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 48: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 49: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 50: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

General Anesthetic in an General Anesthetic in an Oral and Maxillofacial Oral and Maxillofacial

Surgery OfficeSurgery Office NPO IV access Preanesthetic sedative and analgesic

Induction agent/ maintenance agent

Emergence

Recovery Average time 20-30 minutes

No intubation Patient in semi recumbent position

Page 51: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 52: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 53: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 54: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 55: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 56: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103
Page 57: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103

Differences between a Differences between a Hospital GA and an Hospital GA and an

Office GAOffice GA Hospital GA

– Patient intubated– Skeletal muscle relaxant administered (at least for intubation)

– Patient is supine– Inhalational agents used frequently

– Longer anesthesia period

Office GA– No endotracheal tube– Patient is semi supine

– No muscle relaxant– IV agents most frequently used

– Anesthesia duration is less than 30 minutes

Page 58: Clinical Aspect of General Anesthetics James Q. Swift D.D.S. Oral and Maxillofacial Surgery Pharm PHCL 5-103